Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis

Assiut University

Status: Not yet enrolling

Conditions: Ankylosing Spondylitis

Treatments: Device: carotid duplex

Study type: Observational

Funder types: Other

Identifiers

NCT06564155

IL33 in Ankylosing spondylites

Details and patient eligibility

About

detect level of Inturlekin 33 in ankylosing spondyilits patient

measure CIMT (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patients

detect the relation between IL33 and subclinical atherosclerosis in Ankylosinig Spondylitis patients

Full description

Ankylosing spondylitis (AS), a type of SpA, is an autoimmune disease that mainly involves, sacroiliac joints (SIJs) and their adjacent soft tissues, such as tendons and ligaments. The main clinical manifestations include back pain and progressive spinal rigidity as well as inflammation of the hips, shoulders, peripheral joints and fingers/toes. In addition, there are extra-articular manifestations.

Cardiovascular disease has become the first cause of death for patients with ankylosing spondylitis (AS).

Patients with ankylosing spondylitis (AS) have an increased cardiovascular morbidity and mortality . Accelerated atherosclerosis caused by a systemic inflammatory response has been reported to be an important risk factor for increased cardiovascular risk for autoimmune diseases.

Interleukin (IL)-33 is a cytokine belonging to the IL-1 family and was recently identified as a ligand for ST2, .the serum levels of IL-33/sST2 were remarkably higher in the patients with AS than the healthy groups .

Pervious studies confirm the importance of IL-33/ST2 axis in the process of atherosclerosis, and indicate its ambiguous function in immune response, whether as proinflammatory cytokine in advanced atherosclerotic lesions, or as profibrotic, in early lesions.

Previous study shows increased CIMT in AS patients without traditional cardiovascular risk factors compared to healthy controls.

Enrollment: 45 estimated patients

Sex: All

Ages: 20 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patient diagnosed as Ankylosing Spondylitis
• Age (20-40)

Exclusion criteria

• Patients with other rheumatic diseases/other SPA types

  • Participants with history of CVD event in past or present
  • Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months.
  • Patient with other risk factor for atherosclerosis.

Trial design

45 participants in 2 patient groups

ankylosing spondylities patients

Description:

detect level of IL33 in serum of AS patients measure carotid intima media thickness by caroid dupex

Treatment:

Device: carotid duplex

control persons

Description:

detect level of IL33 in serum of normal control group measure carotid intima media thickness by caroid dupex

Treatment:

Device: carotid duplex